Sanofi Bets on mRNA Vaccines After Covid-19 Pandemic Shows Worth

Sanofi Bets on mRNA Vaccines After Covid-19 Pandemic Shows Worth



Sanofi SA said it plans to build a messenger RNA vaccine business, the latest big drugmaker to embrace the technology.

The French pharmaceutical company, one of the world’s biggest vaccine makers by sales, said Tuesday that it would invest €400 million, equivalent to $477 million, a year in mRNA vaccine research, starting immediately.

The drugmaker said it expects the investment to produce at least six new candidate vaccines in human testing by 2025.

The move is a sign of how mRNA technology, which hadn’t produced an approved product before the pandemic but is now a leading source of Covid-19 shots, is reshaping the vaccine industry.

“During the Covid-19 pandemic, mRNA technologies demonstrated potential to deliver new vaccines faster than ever before,” Jean-François Toussaint, R&D chief at Sanofi Pasteur, the company’s vaccine division, said in a statement



Source link

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Share on linkedin
LinkedIn
Rachel Meadows

Rachel Meadows

Trending topics news writer who enjoys cooking, walking her dog and travel.

Related Posts

Enter our 

Las Vegas!

Luxury Resort Stay Giveaway